Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer HOUSTON , Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the

Salarius’ lead program, Seclidemstat, is in a Phase 1 clinical trial for Ewing sarcoma, a rare and devastating pediatric bone and soft-tissue cancer; Early cohort data expected in 2020 HOUSTON , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.

Comprehensive pre-clinical study will test first-in-class investigational therapy Seclidemstat PHOENIX and HOUSTON , Aug. 26, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative

HOUSTON , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that its chief executive officer, David Arthur , issued an open letter to Salarius’ stockholders following the

HOUSTON , July 29, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that President and Chief Executive Officer David Arthur and other members of the management team, will ring the

Completes Sale of HOTSHOT HOUSTON , July 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it completed the sale of HOTSHOT, a novel consumer beverage formerly marketed by Flex

HOUSTON , July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has enrolled the first patient in a Phase 1 clinical study of the company’s lead compound, Seclidemstat, in

To Begin Trading on Nasdaq Capital Market Today Under Ticker Symbol “SLRX” HOUSTON , July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius Pharmaceuticals, LLC ,

Houston, TX, March 18, 2019 – Salarius Pharmaceuticals, LLC , a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that its Chief Executive Officer David Arthur will present at the 29 th  Annual Oppenheimer Healthcare Conference held March 19-20, 2019, at

Flex Pharma and Salarius Pharmaceuticals Announce Merger Agreement to Accelerate Clinical Development of Novel Epigenetic Therapy for Cancer   – Lead Candidate in Clinical Trial for Treating Ewing Sarcoma – – Salarius Completes $6.4 Million Private Placement – – Conference Call and Live Audio